The Pivotal Role of Proteasome Inhibition in Myeloma Treatment

Abstract

The main objectives of this symposium were to explore new insights into the biology of multiple myeloma (MM) in the context of new treatment options, discuss the clinical evidence supporting continuous therapy (CT) as a means of enhancing autologous stem cell transplant (ASCT) outcomes, and explore the modern treatment options for patients with relapsed/refractory MM (RRMM), including proteasome inhibitors (PI). Prof Nikhil C. Munshi introduced the latest research on the biology of MM and its possible translation to the clinic and treatment decisions. Prof Pieter Sonneveld then discussed the current clinical knowledge and evidence for the relative roles of ASCT and CT in treating MM in the context of three clinical questions, with expert panel perspectives on each question. Prof Meletios Dimopoulos closed the symposium with an in-depth look at treatment options for RRMM and the results of the TOURMALINE-MM1 trial. Clinical case studies added relevance to these key learnings and demonstrated the importance of a holistic approach to treatment.